Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025
-
Oasis fans gather in Venice for band reunion film
-
Flick hoping Barca's Yamal can face Valencia after knock
-
Two Nepal rescues revive hopes 10 days after flood
-
Trump envoys land in Moscow for Russia-Ukraine peace push
-
Pogacar to miss worlds after season-ending Vuelta crash
-
Russia hits Kyiv airports as Trump peace envoys awaited
-
Greenwood, Guendouzi handed bans after Fenerbahce-Lyon brawl
-
Nepal tunnel rescue revives hopes 10 days after flood
-
In Iceland, the mystery of the poet, the tomb and the Danish grocer
-
Indonesia rescues second orangutan mother and baby from wildfire
-
Ratko Mladic: Bosnian Serb commander to convicted war criminal
-
Box office magnet Robert Pattinson appears in paedophile thriller
-
Bolivian army base blasts kill two, wound dozens
-
How haze from Indonesian fires impacts Southeast Asia
-
Alcaraz, Sabalenka into US Open last 16 as Williams sisters lose on return
-
Trump sends envoys to Moscow, Kyiv with new plan to 'end war'
-
Williams sisters fall in thrilling return to US Open doubles
-
'Mini-dictatorship': Students slam Argentina-run residence in Paris
-
Bangladesh measles toll nears grim 1,000-child mark
-
The disgraced banker stirring the pot in Brazil's Supreme Court
-
Bolivia farmers return to streets over diesel price hikes
-
Panama Canal begins reducing crossings due to El Nino
-
Tetris distances itself from controversial White House 'arcade' games
-
Trump again seeks to remove protections for wolves
-
Africa bigger, US smaller - UN adopts new map
-
'Getting there' - Alcaraz into US Open last 16 along with Sabalenka
-
Bad weather will not affect All Blacks, says captain Savea
-
Isak ready to show world his quality, says Van Dijk
-
Mbappe misses penalty as Parrott lifts Betis past Real Madrid
-
Stuttgart cruise past Cologne to bounce back from Bayern thumping
-
PSG still winless in Ligue 1 as Monaco go top
-
'Smart, aggressive' Alcaraz into US Open last 16
-
Defending champion Alcaraz reaches last 16 at US Open
-
Isak fires Liverpool to first win under Iraola at Ipswich
-
Lyles ends season before Budapest due to injury flare ups
-
Stocks slip as robust US jobs data stokes rate hike odds
-
US Republicans announce probe into environment groups
-
Mistrial declared in case of US woman who killed her three children
-
Sabalenka survives despite 'tricky' weed smell at US Open
-
Seville, Alfred win at Diamond League finals, Duplantis hit with injury
-
S&P Revises Outlook on Freedom Holding Corp. and Core Subsidiaries to Positive
-
Moody’s Assigns First-Time Insurance Financial Strength Ratings to Freedom Insurance and Freedom Life
-
Job growth but record-high diesel prices -- Trump's midterms mixed bag
-
Trump says envoys taking plan to 'end the war' to Moscow, Kyiv
-
Women's NBA comissioner Engelbert to retire at season's end
-
US Football Hall of Fame revamps selection process
-
Luis Enrique extends contract as PSG coach until 2030
-
Judge declares mistrial in case of US woman who killed her children
-
Duplantis pulls out of Diamond League finals
-
Edgar Davids art thief misses sentencing after being 'knocked out by luggage'
Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025
DENVER, CO / ACCESS Newswire / February 5, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its second quarter of fiscal 2025, after the market close on Wednesday, February 12, 2025. The Company has scheduled a conference call and webcast that same day, Wednesday, February 12, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Wednesday, February 12, 2025, at 4:30 p.m. Eastern time
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 583044.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster4.com/Webcast/Page/2142/51953, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until February 26, 2025 at (877) 481-4010 for U.S. callers or +1 (919) 882-2331 for international callers and using replay access code 51953.
About Aytu BioPharma, Inc.
Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]
Robert Blum or Roger Weiss
Lytham Partners
[email protected]
SOURCE: Aytu BioPharma, Inc
View the original press release on ACCESS Newswire
O.Brown--AT